Tenaya Therapeutics Announces Proposed Public Offering
November 16 2022 - 4:01PM
Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage
biotechnology company with a mission to discover, develop and
deliver potentially curative therapies that address the underlying
causes of heart disease, today announced that it intends to offer
and sell $75 million of shares of common stock in an underwritten
public offering. Tenaya may, in lieu of common stock, offer and
sell to certain investors pre-funded warrants to purchase shares of
its common stock in the underwritten public offering. In addition,
Tenaya intends to grant the underwriters a 30-day option to
purchase up to an additional $11.25 million of shares of its common
stock at the public offering price, less underwriting discounts and
commissions. All of the securities in this offering will be sold by
Tenaya. The proposed offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Morgan Stanley and Piper Sandler are acting as
joint book-running managers for the proposed offering. H.C.
Wainwright & Co. and Chardan are acting as co-lead managers for
the proposed offering.
The shares and pre-funded warrants are being
offered by Tenaya pursuant to a Registration Statement on Form S-3
previously filed and declared effective by the SEC, and Tenaya will
file a preliminary prospectus supplement relating to and describing
the terms of the proposed offering, copies of which can be accessed
for free through the SEC’s website at www.sec.gov.
When available, copies of the preliminary
prospectus supplement and the accompanying prospectus relating to
this offering may also be obtained from: Morgan Stanley & Co.
LLC, Attention: Prospectus Department, 180 Varick Street, 2nd
Floor, New York, NY 10014; or Piper Sandler & Co., 800 Nicollet
Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus
Department, by telephone at (800) 747-3924, or by email at
prospectus@psc.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy, nor will there be any
sale of these securities in any state or other jurisdiction in
which such offer, solicitation, or sale would be unlawful before
registration or qualification under the securities laws of any such
state or jurisdiction.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company
committed to a bold mission: to discover, develop and deliver
curative therapies that address the underlying drivers of heart
disease. Founded by leading cardiovascular scientists from
Gladstone Institutes and the University of Texas Southwestern
Medical Center, Tenaya is developing therapies for rare genetic
disorders as well as for more prevalent heart conditions through
three distinct but interrelated product platforms: Gene Therapy,
Cellular Regeneration and Precision Medicine.
Forward-Looking StatementsThis
press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such statements
include, but are not limited to, statements relating to the
offering, including the timing of the offering, size, and the use
of proceeds. These forward-looking statements are neither promises
nor guarantees and are subject to a variety of risks and
uncertainties, including but not limited to: whether or not Tenaya
will be able to raise capital through the sale of securities or
consummate the offering; the final terms of the offering; the
satisfaction of customary closing conditions; prevailing market
conditions; the anticipated use of the proceeds of the offering
which could change as a result of market conditions or for other
reasons; general economic and market conditions; and other risks.
Information regarding the foregoing and additional risks may be
found in the section entitled “Risk Factors” in documents that
Tenaya files from time to time with the Securities and Exchange
Commission. These forward-looking statements are made as of the
date of this press release, and Tenaya assumes no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact
Michelle Corral
Vice President, Investor Relations and Corporate Communications
Tenaya Therapeutics
IR@tenayathera.com
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Tenaya Therapeutics (NASDAQ:TNYA)
Historical Stock Chart
From Oct 2023 to Oct 2024